A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy.
To demonstrate that Infliximab scheduled maintenance with or without antimetabolites is superior to antimetabolites alone to maintain sustained steroid-free remission over 2 years, while the latter is non inferior with regards to the mean time spent in remission over the same duration
Chief Investigator (UK): Prof. Jack Satsangi
Number and location of participating sites (by region/ country): 20 UK sites, also sites in France, Belgium, Sweden and Germany
EudraCT number: 2014-002311-41
Funder: European Commission
Start and End date of grant award: 2015 - 2021
Current status: Recruitment to the SPARE trial was complete in March 2019. We are now in follow-up and hope to complete in March 2021.
GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with GDPR, please read this document.
UK Sponsor: University of Edinburgh & NHS Lothian ACCORD
CI: Prof Jack Satsangi
Trial Management Team: Christopher White
Research Nurse: Debbie Alexander
ECTU Involvement: Trial Management (UK only), Research Nurses